Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Xtandi Receives Positive CHMP Opinion for Treatment of Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer: Astellas
October 28, 2014
- Univ. of Tokyo, Pfizer Sign Strategic Partnership Deal for Drug Discovery Research
October 28, 2014
- Pfizer Japan Gearing Up for Reorganization in December, Pres. Umeda to Double as Head of New Unit
October 28, 2014
- PII Study Confirms Efficacy of Restless Legs Syndrome Treatment: Hisamitsu
October 28, 2014
- OTC Market Grew to 793 Billion Yen in 2013: Yano Research Institute
October 27, 2014
- Japan Arm of Hengrui Medicine Files Campto Generic for Approval
October 27, 2014
- Astellas Revises Package Insert for Xtandi Following Confirmation of Clinical Benefits in PIII Study
October 27, 2014
- Takeda Gains Worldwide Exclusive Rights for Amitiza Excluding Japan and China from Sucampo
October 24, 2014
- Toray Licenses Hemodialysis Pruritus Treatment to Orient EuroPharma in Taiwan
October 24, 2014
- Global Pharma Market to Reach US$1.3 Trillion by FY2018: IMS Official
October 23, 2014
- Taiho Receives Fast Track Designation from US FDA for Lonsurf
October 23, 2014
- US FDA Accepts sNDA for Fycompa: Eisai
October 23, 2014
- Taisho Files NDA for Anti-Inflammatory Analgesic Patch for Osteoarthritis
October 23, 2014
- Obesity Drug Contrave Hits US Pharmacy Shelves: Takeda
October 23, 2014
- MTPC Downwardly Revises Half-Year, Full-Year Sales Forecasts
October 23, 2014
- Takeda Tops Physician Honoraria Payment List in FY2013
October 22, 2014
- Fujifilm to Ratchet Up Avigan Production for Ebola Treatment
October 21, 2014
- Shionogi Cuts Half-Year Net Profit Projection on Back Taxes
October 21, 2014
- Janssen Files Velcade in Japan for Mantle Cell Lymphoma
October 21, 2014
- Ribomic Ready to Out-License Aptamer-Based Drug RBM007
October 21, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…